Elo Mutual Pension Insurance Co Sells 510 Shares of Agilent Technologies, Inc. (NYSE:A)

Elo Mutual Pension Insurance Co reduced its position in shares of Agilent Technologies, Inc. (NYSE:A) by 1.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,262 shares of the medical research company’s stock after selling 510 shares during the period. Elo Mutual Pension Insurance Co’s holdings in Agilent Technologies were worth $3,404,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Livelsberger Financial Advisory bought a new stake in Agilent Technologies in the fourth quarter valued at approximately $26,000. Crewe Advisors LLC boosted its holdings in Agilent Technologies by 114.8% in the second quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 101 shares during the last quarter. Ridgewood Investments LLC bought a new stake in Agilent Technologies in the second quarter valued at approximately $29,000. Rise Advisors LLC boosted its holdings in Agilent Technologies by 527.8% in the first quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 190 shares during the last quarter. Finally, YHB Investment Advisors Inc. bought a new stake in Agilent Technologies in the first quarter valued at approximately $34,000. 87.42% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on A. UBS Group upped their target price on Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a report on Thursday, August 22nd. Citigroup upped their target price on Agilent Technologies from $150.00 to $165.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Wolfe Research cut Agilent Technologies from an “outperform” rating to a “peer perform” rating in a report on Thursday, June 27th. Barclays increased their price target on Agilent Technologies from $125.00 to $135.00 and gave the stock an “underweight” rating in a report on Friday, August 23rd. Finally, JPMorgan Chase & Co. cut their price target on Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating on the stock in a report on Thursday, May 30th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Agilent Technologies has an average rating of “Moderate Buy” and an average price target of $141.60.

Insider Transactions at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction on Friday, July 26th. The stock was sold at an average price of $140.00, for a total value of $274,120.00. Following the completion of the sale, the chief executive officer now directly owns 26,076 shares of the company’s stock, valued at approximately $3,650,640. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.33% of the stock is owned by insiders.

Agilent Technologies Price Performance

Shares of NYSE:A opened at $139.01 on Thursday. The company has a quick ratio of 1.37, a current ratio of 1.78 and a debt-to-equity ratio of 0.36. Agilent Technologies, Inc. has a twelve month low of $96.80 and a twelve month high of $155.35. The stock’s 50 day moving average is $137.50 and its 200-day moving average is $139.25. The firm has a market capitalization of $40.56 billion, a price-to-earnings ratio of 32.86, a PEG ratio of 6.43 and a beta of 1.05.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.26 by $0.06. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The company had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same period in the prior year, the firm earned $1.43 earnings per share. Agilent Technologies’s revenue for the quarter was down 5.6% on a year-over-year basis. Sell-side analysts forecast that Agilent Technologies, Inc. will post 5.24 EPS for the current fiscal year.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.